Homocysteine levels in patients with risk factors for atherosclerosis

被引:10
作者
Blum, A [1 ]
Lupovitch, S
Khazim, K
Peleg, A
Gumanovsky, M
Yeganeh, S
Jawabreh, S
机构
[1] Poria Hosp, Dept Internal Med, IL-15208 Lower Galilee, Israel
[2] Poria Hosp, Dept Clin Chem, IL-15208 Lower Galilee, Israel
[3] Technion Israel Inst Technol, Fac Med, Haifa, Israel
关键词
homocysteine; atherosclerosis; coronary artery disease;
D O I
10.1002/clc.4960240609
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Abundant epidemiological evidence has demonstrated that the presence of mild to moderate hyperhomocysteinemia is an independent risk factor for atherosclerosis in the coronary, cerebral, and peripheral vasculature, and for vascular disease, including coronary disease. It has been demonstrated that plasma total homocysteine level is a strong predictor of mortality in patients with angiographically confirmed coronary artery disease. Hypothesis: The study was undertaken to determine the extent of homocysteine levels in patients without documented coronary artery disease, but with at least one risk factor for atherosclerosis. Methods: Fasting blood samples were collected prospectively from 160 consecutive patients (50 women and 110 men, mean age 65 +/- 7 years) who had at least one risk factor for atherosclerosis, but had no documented coronary artery disease. Homocysteine levels were measured by an immunoassay method. Results: Of the patients studied, 78 (48.75%) with at least one risk factor for atherosclerosis had high homocysteine levels; 62 patients had mild hyperhomocysteinemia (15-30 mu mol/l); and 16 patients had moderate hyperhomocysteinemia (30-100 mu mol/l). Conclusions: Our data suggest that hyperhomocysteinemia is highly prevalent in patients with risk factors for atherosclerosis. Homocysteine level (an independent convertible risk factor to atherosclerosis) should be measured routinely in patients with risk factors for atherosclerosis and treated appropriately.
引用
收藏
页码:463 / 466
页数:4
相关论文
共 29 条
[1]  
ARENSEN E, 1995, INT J EPIDEMIOL, V24, P704
[2]   A QUANTITATIVE ASSESSMENT OF PLASMA HOMOCYSTEINE AS A RISK FACTOR FOR VASCULAR-DISEASE - PROBABLE BENEFITS OF INCREASING FOLIC-ACID INTAKES [J].
BOUSHEY, CJ ;
BERESFORD, SAA ;
OMENN, GS ;
MOTULSKY, AG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (13) :1049-1057
[3]   Hyperhomocysteinemia as a risk factor for deep-vein thrombosis [J].
denHeijer, M ;
Koster, T ;
Blom, HJ ;
Bos, GMJ ;
Briet, E ;
Reitsma, PH ;
Vandenbroucke, JP ;
Rosendaal, FR .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (12) :759-762
[4]   HOMOCYSTEINE, A RISK FACTOR FOR PREMATURE VASCULAR-DISEASE AND THROMBOSIS, INDUCES TISSUE FACTOR ACTIVITY IN ENDOTHELIAL-CELLS [J].
FRYER, RH ;
WILSON, BD ;
GUBLER, DB ;
FITZGERALD, LA ;
RODGERS, GM .
ARTERIOSCLEROSIS AND THROMBOSIS, 1993, 13 (09) :1327-1333
[5]   EFFECT OF HOMOCYSTEINE AND HOMOCYSTINE ON PLATELET AND VASCULAR ARACHIDONIC-ACID METABOLISM [J].
GRAEBER, JE ;
SLOTT, JH ;
ULANE, RE ;
SCHULMAN, JD ;
STUART, MJ .
PEDIATRIC RESEARCH, 1982, 16 (06) :490-493
[6]   Plasma homocysteine as a risk factor for vascular disease - The European concerted action project [J].
Graham, IM ;
Daly, LE ;
Refsum, HM ;
Robinson, K ;
Brattstrom, LE ;
Ueland, PM ;
PalmaReis, RJ ;
Boers, GHJ ;
Sheahan, RG ;
Israelsson, B ;
Uiterwaal, CS ;
Meleady, R ;
McMaster, D ;
Verhoef, P ;
Witteman, J ;
Rubba, P ;
Bellet, H ;
Wautrecht, JC ;
deValk, HW ;
Luis, ACS ;
ParrotRoulaud, FM ;
Tan, KS ;
Higgins, I ;
Garcon, D ;
Medrano, MJ ;
Candito, M ;
Evans, AE ;
Andria, G .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (22) :1775-1781
[7]   HOMOCYSTEINE-INDUCED MODULATION OF TISSUE-PLASMINOGEN ACTIVATOR BINDING TO ITS ENDOTHELIAL-CELL MEMBRANE-RECEPTOR [J].
HAJJAR, KA .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (06) :2873-2879
[8]   HOMOCYSTINE-INDUCED ARTERIOSCLEROSIS - ROLE OF ENDOTHELIAL CELL INJURY AND PLATELET RESPONSE IN ITS GENESIS [J].
HARKER, LA ;
ROSS, R ;
SLICHTER, SJ ;
SCOTT, CR .
JOURNAL OF CLINICAL INVESTIGATION, 1976, 58 (03) :731-741
[9]   HOMOCYSTEINE AND OTHER SULFHYDRYL COMPOUNDS ENHANCE THE BINDING OF LIPOPROTEIN(A) TO FIBRIN - A POTENTIAL BIOCHEMICAL LINK BETWEEN THROMBOSIS, ATHEROGENESIS, AND SULFHYDRYL COMPOUND METABOLISM [J].
HARPEL, PC ;
CHANG, VT ;
BORTH, W .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (21) :10193-10197
[10]  
HEINECKE JW, 1987, J BIOL CHEM, V262, P10098